Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

PURPOSE: Sacituzumab govitecan (SG) is an antibody–drug conjugate composed of an anti–Trop-2 antibody coupled to SN-38 via a proprietary hydrolyzable linker. In the ASCENT study, SG improved survival versus single-agent treatment of physician’s choice (TPC) in pre-treated metastatic triple-negative...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Shaughnessy, Joyce, Brufsky, Adam, Rugo, Hope S., Tolaney, Sara M., Punie, Kevin, Sardesai, Sagar, Hamilton, Erika, Loirat, Delphine, Traina, Tiffany, Leon-Ferre, Roberto, Hurvitz, Sara A., Kalinsky, Kevin, Bardia, Aditya, Henry, Stephanie, Mayer, Ingrid, Zhu, Yanni, Phan, See, Cortés, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374646/
https://www.ncbi.nlm.nih.gov/pubmed/35545724
http://dx.doi.org/10.1007/s10549-022-06602-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374646/
https://www.ncbi.nlm.nih.gov/pubmed/35545724
http://dx.doi.org/10.1007/s10549-022-06602-7

Ejemplares similares